Silence Therapeutics has appointed chief business officer Tony Sedgwick as its new CEO following the resignation of Thomas Christely.
Sedgwick joined Silence last September. Before that, he was CEO of Novacta, Daniolabs, and Cambridge Biotechnology.
Christely was previously CEO of Atugen, which was later acquired by Silence. He had served as Silence's COO until the departure of former CEO Philip Haworth last year. Silence said that Christely has also resigned his board seat.